Compare Bristol-Myers Squibb Co (BMY) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs QUALCOMM, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while QUALCOMM, Inc. trades at $179.9 (market cap $187.72B). The key difference: QUALCOMM, Inc. is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | QCOM | |
|---|---|---|
Market Cap | $116.30B | $187.72B |
Sector | Health | Technology |
52-Week High | $62.37 | $251.10 |
52-Week Low | $42.60 | $124.07 |
Enterprise Value | $152.24B | $193.19B |
Dividend Yield | 4.42% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Qualcomm (QCOM) trades at $183.98, down 2.74% on the day, amid a bearish technical signal. The company maintains strong profitability with 54.8% gross margins and 22.31% net income margin, though revenue growth has been modest. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.56 estimate. Analyst consensus remains positive with a $222.53 price target, representing 21% upside potential from current levels.
Qualcomm faces near-term headwinds from smartphone market softness but is successfully diversifying into automotive and AI data centers. The stock offers value at 19.15x P/E with strong cash flow generation, though competition from Nvidia in PC chips presents execution risk. With 42.65% of analysts rating it Buy and solid balance sheet fundamentals, QCOM presents a compelling long-term opportunity despite technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
